Diagnostic Value of Radiomics in Predicting Ki-67 and Cytokeratin 19 Expression in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jan 18

PMID 38234405

Authors

Lu Zhou

Yiheng Chen

Yan Li

Chaoyong Wu

Chongxiang Xue

Xihong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Radiomics have been increasingly used in the clinical management of hepatocellular carcinoma (HCC), such as markers prediction. Ki-67 and cytokeratin 19 (CK-19) are important prognostic markers of HCC. Radiomics has been introduced by many researchers in the prediction of these markers expression, but its diagnostic value remains controversial. Therefore, this review aims to assess the diagnostic value of radiomics in predicting Ki-67 and CK-19 expression in HCC.

Methods: Original studies were systematically searched in PubMed, EMBASE, Cochrane Library, and Web of Science from inception to May 2023. All included studies were evaluated by the radiomics quality score. The C-index was used as the effect size of the performance of radiomics in predicting Ki-67and CK-19 expression, and the positive cutoff values of Ki-67 label index (LI) were determined by subgroup analysis and meta-regression.

Results: We identified 34 eligible studies for Ki-67 (18 studies) and CK-19 (16 studies). The most common radiomics source was magnetic resonance imaging (MRI; 25/34). The pooled C-index of MRI-based models in predicting Ki-67 was 0.89 (95% CI:0.86-0.92) in the training set, and 0.87 (95% CI: 0.82-0.92) in the validation set. The pooled C-index of MRI-based models in predicting CK-19 was 0.86 (95% CI:0.81-0.90) in the training set, and 0.79 (95% CI: 0.73-0.84) in the validation set. Subgroup analysis suggested Ki-67 LI cutoff was a significant source of heterogeneity ( = 0.0% 0.05), and meta-regression showed that the C-index increased as Ki-67 LI increased.

Conclusion: Radiomics shows promising diagnostic value in predicting positive Ki-67 or CK-19 expression. But lacks standardized guidelines, which makes the model and variables selection dependent on researcher experience, leading to study heterogeneity. Therefore, standardized guidelines are warranted for future research.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023427953.

References

Lu M, Qu Q, Xu L, Zhang J, Liu M, Jiang J . Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. Acad Radiol. 2022; 30(5):841-852. DOI: 10.1016/j.acra.2022.12.018. View

Lv J, Yin H, Yu H, Shi H . The added value of F-FDG PET/MRI multimodal imaging in hepatocellular carcinoma for identifying cytokeratin 19 status. Abdom Radiol (NY). 2023; 48(7):2331-2339. DOI: 10.1007/s00261-023-03911-3. View

Jing M, Cao Y, Zhang P, Zhang B, Lin X, Deng L . The Benefit of Apparent Diffusion Coefficient in Evaluating the Invasiveness of Hepatocellular Carcinoma. Front Oncol. 2021; 11:719480. PMC: 8423087. DOI: 10.3389/fonc.2021.719480. View

Fan Y, Yu Y, Wang X, Hu M, Hu C . Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma. BMC Med Imaging. 2021; 21(1):100. PMC: 8204550. DOI: 10.1186/s12880-021-00633-0. View

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P . Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4):441-6. PMC: 4533986. DOI: 10.1016/j.ejca.2011.11.036. View

Yao Z, Dong Y, Wu G, Zhang Q, Yang D, Yu J . Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images. BMC Cancer. 2018; 18(1):1089. PMC: 6233500. DOI: 10.1186/s12885-018-5003-4. View

Scholzen T, Gerdes J . The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22. DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. View

Kim H, Choi G, Na D, Ahn E, Kim G, Lee J . Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011; 54(5):1707-17. DOI: 10.1002/hep.24559. View

Wang H, Yang C, Zeng M, Rao S, Ji Y, Weng X . Magnetic resonance texture analysis for the identification of cytokeratin 19-positive hepatocellular carcinoma. Eur J Radiol. 2019; 117:164-170. DOI: 10.1016/j.ejrad.2019.06.016. View

10.

Chen Y, Qin X, Long L, Zhang L, Huang Z, Jiang Z . Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma. J Magn Reson Imaging. 2019; 51(6):1755-1763. DOI: 10.1002/jmri.26974. View

11.

Zhao Y, Tan X, Chen J, Tan H, Huang H, Luo P . Preoperative prediction of cytokeratin-19 expression for hepatocellular carcinoma using T1 mapping on gadoxetic acid-enhanced MRI combined with diffusion-weighted imaging and clinical indicators. Front Oncol. 2023; 12:1068231. PMC: 9893005. DOI: 10.3389/fonc.2022.1068231. View

12.

Hu X, Wang Q, Huang G, He X, Sparrelid E, Brismar T . Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma. Comput Math Methods Med. 2023; 2023:5424204. PMC: 9940957. DOI: 10.1155/2023/5424204. View

13.

Hu X, Zhou J, Li Y, Wang Y, Guo J, Sack I . Added Value of Viscoelasticity for MRI-Based Prediction of Ki-67 Expression of Hepatocellular Carcinoma Using a Deep Learning Combined Radiomics (DLCR) Model. Cancers (Basel). 2022; 14(11). PMC: 9179448. DOI: 10.3390/cancers14112575. View

14.

Zhao Y, Xiong X, Chen K, Tang W, Yang X, Shi Z . Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery. Front Oncol. 2021; 11:605234. PMC: 7947851. DOI: 10.3389/fonc.2021.605234. View

15.

Chen Y, Chen J, Zhang Y, Lin Z, Wang M, Huang L . Preoperative Prediction of Cytokeratin 19 Expression for Hepatocellular Carcinoma with Deep Learning Radiomics Based on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. J Hepatocell Carcinoma. 2021; 8:795-808. PMC: 8314931. DOI: 10.2147/JHC.S313879. View

16.

Debray T, Damen J, Riley R, Snell K, Reitsma J, Hooft L . A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes. Stat Methods Med Res. 2018; 28(9):2768-2786. PMC: 6728752. DOI: 10.1177/0962280218785504. View

17.

Zhuo J, Lu D, Tan W, Zheng S, Shen Y, Xu X . CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. J Cancer. 2020; 11(17):5069-5077. PMC: 7378918. DOI: 10.7150/jca.44697. View

18.

Hu X, Yang Z, Liang H, Ding Y, Grimm R, Fu C . Whole-tumor MRI histogram analyses of hepatocellular carcinoma: Correlations with Ki-67 labeling index. J Magn Reson Imaging. 2016; 46(2):383-392. DOI: 10.1002/jmri.25555. View

19.

Huang Z, Zhou P, Li S, Li K . Prediction of the Ki-67 marker index in hepatocellular carcinoma based on Dynamic Contrast-Enhanced Ultrasonography with Sonazoid. Insights Imaging. 2022; 13(1):199. PMC: 9763522. DOI: 10.1186/s13244-022-01320-6. View

20.

Yan C, Han Z, Chen X, Gao L, Ye R, Li Y . Diffusion-Weighted Imaging as a Quantitative Imaging Biomarker for Predicting Proliferation Rate in Hepatocellular Carcinoma: Developing a Radiomics Nomogram. J Comput Assist Tomogr. 2023; 47(4):539-547. PMC: 10348622. DOI: 10.1097/RCT.0000000000001448. View